SHANGHAI, June 5, 2026 /PRNewswire/ -- On May 20, 2026, Aphranel® celebrated its first anniversary at the Waldorf Astoria Shanghai on the Bund, marking a major milestone in the brand's international presence in regenerative aesthetics.
One year earlier, on May 8, 2025, Aphranel® officially launched globally in Shanghai after obtaining China's first approval for a Calcium Hydroxyapatite (CaHA) Microsphere Injectable Facial Filler. At the time, many questioned how far a regenerative aesthetics brand built on long-term scientific research and biomaterial innovation could go.One year later, Aphranel® has demonstrated both scientific credibility and market acceptance.Within its first year on the market, cumulative product deliveries across China exceeded 150,000 syringes. The brand expanded across 28 provinces and 94 cities in China, partnered with more than 620 medical clinics, and certified over 700 physicians nationwide.In an increasingly competitive regenerative aesthetics market, Aphranel® moved from launch to broad clinical adoption within just 12 months.During the anniversary summit, Aphranel® announced that it had obtained European Union Medical Device Regulation (EU MDR) certification under Regulation (EU) 2017/745.With this achievement, Aphranel® became the first China-originated and China-manufactured facial injectable filler to obtain EU MDR certification and the first CaHA microsphere facial injectable filler from the Asia-Pacific region certified under the EU MDR framework.
